Company news
Oric Pharmaceuticals, Inc. news in 2021
Oric Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
December 12, 2021
ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma
December 8, 2021
ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
November 9, 2021
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
November 7, 2021
ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
November 3, 2021
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC
October 6, 2021
ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 29, 2021
ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
September 20, 2021
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
August 15, 2021
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
August 9, 2021
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
June 27, 2021
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
June 1, 2021
ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 25, 2021
ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel
May 24, 2021
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
May 5, 2021
ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting
April 27, 2021
ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
April 11, 2021
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
March 22, 2021
ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 9, 2021
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones
January 10, 2021
ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 3, 2021
Decks in 2021
- Investor Presentation (January 2021)
Investor deck · 41 slides · Jan 11, 2021